These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38380162)

  • 1. A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers.
    Sharma AK; Rastogi S; Ali F; Yadav AP; Goyal RK
    Saudi Pharm J; 2024 Mar; 32(3):101985. PubMed ID: 38380162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between Branded and Generic Furosemide 40 mg Tablets Using Thermal Gravimetric Analysis and Fourier Transform Infrared Spectroscopy.
    Arafat M; Fahelelbom KM; Sarfraz MK; Bostanudin MF; Sharif QU; Esmaeil A; Al Hanbali OA; Aburuz S
    J Pharm Bioallied Sci; 2020; 12(4):489-498. PubMed ID: 33679098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
    J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study.
    George T; Baliga MS
    Cureus; 2021 Nov; 13(11):e19231. PubMed ID: 34877208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study.
    Han SH; Oh GC; Kwon HM; Park CG; Kim IJ; Hwang GS; Yoo BS; Park SH; Lee KJ; Kim HS
    Drug Des Devel Ther; 2018; 12():4217-4229. PubMed ID: 30587918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Physical Properties of Generic and Branded Travoprost Formulations.
    Wadhwani M; Mishra SK; Angmo D; Velpandian T; Sihota R; Kotnala A; Bhartiya S; Dada T
    J Curr Glaucoma Pract; 2016; 10(2):49-55. PubMed ID: 27536047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
    Jones MR; Sealey JE; Laragh JH
    Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India.
    Singal GL; Nanda A; Kotwani A
    Indian J Pharmacol; 2011 Apr; 43(2):131-6. PubMed ID: 21572645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.
    Al Ameri MN; Nayuni N; Anil Kumar KG; Perrett D; Tucker A; Johnston A
    Results Pharma Sci; 2012; 2():1-8. PubMed ID: 25755988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
    CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
    Gopireddy RR; Maruthapillai A; Mahapatra S
    J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of the transition from branded to generic oncology drugs.
    Cheung WY; Kornelsen EA; Mittmann N; Leighl NB; Cheung M; Chan KK; Bradbury PA; Ng RCH; Chen BE; Ding K; Pater JL; Tu D; Hay AE
    Curr Oncol; 2019 Apr; 26(2):89-93. PubMed ID: 31043808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
    Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
    J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.